29th Nov 2013 07:00
TOTAL VOTING RIGHTS
VERNALIS PLC (the "Company")
29 November 2013
Vernalis plc (LSE: VER) announces that for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 442,125,765 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.
The total number of voting rights in the Company is therefore 442,125,765.
The above figure of 442,125,765 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the Disclosure and Transparency Rules.
Enquiries:
Vernalis Contacts: | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Oriel Securities Limited: | +44 (0) 20 7710 7600 |
Juliet Thompson Jonathan Senior
| |
Brunswick Group: | +44 (0) 20 7404 5959 |
Jon Coles
|
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Related Shares:
Vernalis PLC